GH Research PLC — Company profile
Healthcare · Biotechnology · Ireland
Last price 21.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Details
| Name | GH Research PLC |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 73 |
| Founded | 2018 |
| Ipo Date | 2021-06-25 |
| Ceo | Velichka Valcheva |
| Country | Ireland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | IE000GID8VI0 |
| Cusip | G3855L106 |
| Cik | 1855129 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer |
| Florian Schonharting M.Sc. (Econ) | Co-Founder and Non-Executive Chairman of the Board |
| Magnus Halle | Co-Founder and MD of Ireland |
| Julie Ryan F.C.A. | Vice President of Finance |
| Aaron Cameron M.B.A. | Chief Operating Officer |
Contact
| Address | Joshua Dawson House, Dawson Street, Dublin, D02 RY95, Ireland |
| Phone | 353 1 437 8334 |
| Website | https://www.ghres.com |